Dr Dan Hayes
University of Michigan, Ann Arbor, USA
Dr. Hayes received undergraduate, master’s and medical degrees from Indiana University, followed by a residency in internal medicine at the University of Texas Southwestern Medical School/Health Science Center/Parkland Memorial Hospital and a fellowship in medical oncology at Harvard’s Dana Farber Cancer Institute (DFCI). He has led the breast cancer programs at DFCI (1991-1996), Georgetown University’s Lombardi Cancer Center (1996-2001), and the University of Michigan from 2001-2016.
Dr. Hayes’ research interests are in the field of experimental therapeutics and cancer biomarkers, especially in breast cancer. His work has been particularly focused on development and validation of cancer biomarker tests, such as HER-2, CA15-3, circulating tumor cells and pharmacogenomic markers. He has been instrumental in establishing international guidelines for the use of tumor biomarker tests, including criteria for their clinical utility.
He has served as chair of the SWOG Breast Cancer Translational Medicine Committee, and he was an inaugural member and chaired the American Society of Clinical Oncology (ASCO) Tumor Marker Guidelines Committee. He has been instrumental in the joint ad hoc committees between ASCO and the College of American Pathologists. Dr. Hayes served on the ASCO Board of Directors, and served a 3 year term as President of ASCO from 2016-2018. He is a Fellow of ASCO, a Fellow of the American College of Physicians, a past Komen Scholar, and a member of the Association of American Physicians and of the American Clinical and Climatologic Association. He has been the recipient of the ASCO Gianni Bonadonna Award in breast cancer and the Allen Lichter Visionary Leadership Award in 2021 as well as the Susan G. Komen Brinker Award for Scientific Distinction in Clinical Research in 2023.
Clinical implications of late recurrence/dormancy
Adjuvant systemic therapy (AST) has dramatically improved outcomes for patients with newly diagnosed breast cancer, and appropriate use of tumor biomarkers (TBs) has permitted judicious application of AST, identifying those who do not need it, and those for whom specific types of AST will not work. These TBs include estrogen receptor (ER), HER2, multi-gene expression genomic assays, and germline susceptibility assays.Adjuvant endocrine therapy (ET) has arguably been the most beneficial therapy in all of oncology in regards to lives saved, given the incidence of ER positive breast cancer and the potency of the treatment. However, although the benefits of adjuvant ET for positive breast in the first five year safter diagnosis are substantial, ER positive micrometastases can remain in dormancy and re-appear as metastases years or even decades after diagnosis, even in women who have taken ET for 5 years. One of the great challenges in modern oncology is to define which patients still have microscopic metastases, which of these is likely to remain in dormancy or more importantly escape from it, and what therapeutic approaches should be taken to prevent this circumstance.These issues will be discussed in the presentation
UKIBCS
Please contact the conference secretariat:
t: 01332 227776
e: ukibcs@kc-jones.co.uk